Agenus (NASDAQ:AGEN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Agenus (NASDAQ:AGEN) in a research report released on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Several other brokerages have also recently weighed in on AGEN. B. Riley decreased their price target on shares of Agenus from $120.00 to $100.00 and set a buy rating for the company in a research note on Monday, March 18th. HC Wainwright reaffirmed a buy rating and issued a $160.00 target price on shares of Agenus in a research report on Thursday, March 14th.

Agenus Trading Up 6.8 %

Shares of NASDAQ AGEN opened at $5.31 on Wednesday. The company has a fifty day moving average price of $11.67 and a 200 day moving average price of $14.18. The firm has a market cap of $111.22 million, a PE ratio of -0.37 and a beta of 1.26. Agenus has a 1-year low of $4.78 and a 1-year high of $42.60.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The firm had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million. Equities research analysts forecast that Agenus will post -8.21 EPS for the current year.

Insider Buying and Selling at Agenus

In related news, insider Garo H. Armen acquired 25,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were bought at an average price of $13.00 per share, for a total transaction of $325,000.00. Following the purchase, the insider now directly owns 31,298 shares in the company, valued at approximately $406,874. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its stake in Agenus by 3,008.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 2,232,064 shares during the last quarter. Swiss National Bank increased its position in Agenus by 5.9% during the third quarter. Swiss National Bank now owns 690,100 shares of the biotechnology company’s stock worth $780,000 after buying an additional 38,600 shares during the last quarter. Citigroup Inc. raised its stake in Agenus by 41.0% in the third quarter. Citigroup Inc. now owns 707,213 shares of the biotechnology company’s stock valued at $799,000 after buying an additional 205,817 shares during the period. Exchange Traded Concepts LLC lifted its position in shares of Agenus by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 27,137 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Agenus by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 107,291 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 15,370 shares during the period. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.